🇺🇸

US SEC Filing Intelligence

· daily

S&P 500 Healthcare Sector SEC Filings — April 02, 2026

Across 50 filings in the USA S&P 500 Healthcare intelligence stream (with broader financial and sector crossovers), dominant themes include a heavy proxy season with 15+ DEF 14A/DEFA14A filings scheduling virtual annual meetings in May 2026 for director elections, auditor ratifications, and equity plan approvals; frequent C-level transitions (9 CFO/COO/CEO changes or appointments); and financing maneuvers like new $400M+ term loans and maturity extensions. Period-over-period trends show selective revenue acceleration (e.g., Vertex $12B total 2025 revenues driven by CF franchise; BD Q1 FY2026 revenues +3.5% YoY to $4.486B, GAAP op income +66% to $468M) amid mixed adjusted metrics (BD adj EPS -10.1% YoY) and comp variances (ENB PEO +3% YoY to $604K, NEOs -39% to $335K). Healthcare-specific highlights feature biotech trial catalysts (Roivant brepocitinib PDUFA Q3 2026 despite Immunovant Phase 3 failures) and device/financing positives (Caris $400M term loan, BD momentum in CASGEVY/JOURNAVX). Capital allocation leans toward equity incentives and buybacks ($1B News Corp program), with neutral-to-positive sentiment (60%+ positive/neutral). Portfolio implications: monitor May proxy outcomes for governance shifts and Q2/Q3 biotech catalysts amid leadership churn signaling potential strategic pivots.

30 high priority 20 medium 50 total filings
· daily

US Executive Compensation Proxy SEC Filings — April 02, 2026

Across 50 DEF 14A proxy statements filed April 2, 2026, for 2026 AGMs primarily in mid-May, companies overwhelmingly highlight robust 2025 performance with revenue growth averaging 7-13% YoY where reported (e.g., Equinix +5%, Cohu +13%, Oceaneering +5%), strong shareholder returns via $569M at Empire State Realty, $450M buybacks at Primerica, and dividend increases at Phillips 66 (+10%), UDR (+1.2% for 213th consecutive), and Solstice (first dividend March 2026). Executive compensation is heavily performance-tied (e.g., 95% at-risk for Equinix CEO, 88% Iridium CEO), with governance features like clawbacks, stock ownership (CEO 6x salary at Iridium/First Solar), and independent boards prevalent; sentiments skew positive/neutral (38/50), mixed in 4 cases with declines (Primerica Term Life -10.4% policies, Cohu GAAP loss $(1.59)/share). Portfolio-level trends show margin expansion in select cases (Tenable +140 bps, Waste Connections outsized), capital allocation favoring buybacks/dividends over M&A in most, but outliers like Horizon Space SPAC deadline extension signal risks; implies broad market resilience but watch REITs/financials for relative outperformance amid clustered AGM catalysts May 12-22.

50 high priority 50 total filings
· daily

US IPO Pipeline SEC S-1 Filings — April 02, 2026

Three S-1 filings on April 2, 2026, signal a nascent IPO pipeline resurgence, featuring a blank-check SPAC (Churchill Capital Corp XII), a multi-geography operating company (TG-17, Inc.), and a consulting firm (Invech Holdings, Inc.), all with high materiality (9-10/10). Limited period-over-period data shows TG-17's balance sheets for Dec 31, 2024 vs 2025 with ongoing operations across US/Israel/France, but no YoY revenue/margin trends disclosed; subsequent events include stock issuances Jan-Mar 2026 indicating capital raises amid customer concentration risks. Churchill's sponsor commitment via 11.5M founder shares (post 2.875M surrender on Mar 16, 2026) and 350k private units highlights SPAC alignment, while Invech flags substantial going concern doubts with no adjustments. Neutral sentiment dominates (2/3 filings), but mixed for Invech underscores pre-IPO risks; no insider trading patterns, forward guidance, or capital returns noted across filings. Portfolio-level theme: High-risk IPO candidates with dilution potential from cheap founder shares/preferred stock, warranting watch for effectiveness and pricing catalysts amid neutral-to-mixed outlook.

3 high priority 3 total filings
· daily

Global High-Priority Regulatory Events — April 02, 2026

Across 50 filings in the Global High Priority Market Events stream (US SEC focus, April 2, 2026), dominant themes include SPAC/business combinations (Suncrete, Crown Reserve), debt refinancings/exchanges (Caris, Terra Property), M&A (Kodiak), and restructuring schemes (Hindware, Aster DM, Narayana), signaling portfolio-level deleveraging and consolidation amid critical events like bankruptcies/insolvencies. Period-over-period trends show mixed financial health: strong revenue growth in biotech/pharma (Pharming +26.6% YoY to $376M, DYNARESOURCE +25.7% to $58M) and services (FactSet +7% YoY to $611M Q1), but sharp declines in ecommerce (LightInTheBox -59.5% YoY to $255M) and persistent losses (Pharvaris net loss +31% YoY to €176M); margins stable/improving in Pharming (~88%) but compressing elsewhere. Capital allocation leans toward buybacks (FactSet $303M H1) and dividends (Burford 6.25¢), with insider conviction limited but positive executive hires (Booking, ESAB, Sally Beauty). Forward-looking catalysts cluster in H2 2026 (OS Therapies approvals) and May AGMs, implying near-term volatility but alpha in accretive deals. REITs (Ashford, Service Properties) show asset sales and share increases for flexibility, while healthcare schemes (15/50 filings) indicate restructuring tailwinds. Overall, bullish on biotech/energy M&A, bearish on microcaps with going concerns.

50 high priority 50 total filings
· daily

US Earnings Financial Results SEC Filings — April 02, 2026

Across 19 US SEC filings for Q1/FY2025-2026 financial results, results are predominantly mixed (17/19), with revenue growth in 10 companies averaging +22% YoY (led by Navan +31%, Regional Health +190%, DYNA +26%), but declines in 7 averaging -20% YoY (Lindsay -16%, Lovesac other -37%); margins compressed in 7 firms by avg -150bps (Lovesac -210bps, Caleres -190bps, IRIDEX -460bps). Net income swings to profit in 5 (DYNA from -$8.5M to +$3.8M, Regional Health from -$3.2M to +$3.4M), while losses narrowed in 4 but widened in others; operating cash flow improved in 8/15 reported (FactSet +28%, Acuity +20%). Capital allocation favors buybacks ($303M FactSet, $103M Acuity, $80M TD SYNNEX, $56M Lindsay), signaling management conviction amid $1B+ total returns, though cash piles declined QoQ in 10/16 (TD SYNNEX -36%, Acuity -36%). Microcaps face acute risks (Algorhythm going concern, Vitaspring $3.5M deficit), SPACs (Iron Horse, Starry Sea) build trust accounts post-IPO, and medtech/retail show segment shifts (ChargePoint subscriptions +13% mix). Portfolio implication: Favor buyback-heavy mid/large caps (TD SYNNEX, FactSet) for stability, avoid cash-burn shells (Byrn, Vitaspring); sector rotation to distribution/mining growth.

19 high priority 19 total filings
· daily

US SEC Trading Suspension Halt Orders — April 02, 2026

Across five US-listed small-cap companies, a cluster of Nasdaq and NYSE listing compliance failures emerged in late March-early April 2026, primarily driven by sub-$1.00 bid prices (3/5 filings), low market value of listed securities (1/5), governance issues (1/5), and insufficient market cap (1/5), signaling broad small-cap distress amid low valuations. No period-over-period financial trends like revenue growth or margins are detailed, but prior non-compliance periods (e.g., CytoSorbents' initial 180 days ending March 31, 2026) highlight persistent deterioration in stock price and market value metrics over 30-180 day windows. Most receive 180-day compliance extensions to September 2026 with no immediate delisting, except Solo Brands facing NYSE delisting proceedings starting April 2, 2026, and OTC transition. Sentiments skew negative/mixed (3 negative, 2 mixed), with high materiality (avg 9/10), implying elevated delisting risks, potential reverse splits, and liquidity erosion. Portfolio-level pattern: 4/5 emerging growth companies, concentrated Nasdaq issues (80%), pointing to sector-wide undervaluation or operational challenges in biotech/tech/consumer spaces. Market implications include heightened volatility, OTC trading discounts, and short-term trading opportunities around appeals/compliance catalysts.

5 high priority 5 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — April 02, 2026

Across 50 8-K filings in the USA Corporate Distress & Bankruptcy stream (39 new), distress signals dominate with 6 Nasdaq compliance failures (bid price/MVLS/audit committee deficiencies, extensions to Sep 2026), 4 reverse stock splits (1:20 to 1:25 ratios), 5+ debt forbearances/amendments/CRO appointments signaling liquidity crunches, and litigation settlements amid ongoing obligations. Counterbalancing positives include 10+ equity offerings/PP/IPOs raising $200M+ (e.g., $400M Caris loan, $42M Summit), debt exchanges/refinancings (e.g., Terra $25.6M secured notes), and M&A (Nuveen/PCAP acquisition Q2 2026). No explicit YoY/QoQ revenue/margin trends disclosed, but implied deteriorations from overadvances ($16M Borealis obligations), Nasdaq sub-$1 bids, and min cash covenants ($50M Caris). Portfolio-level: Small-cap biotechs/healthcare lead distress (12/50), with capital allocation skewed to dilutive raises vs dividends/buybacks (0 reported); insider activity limited to exec separations (#17 Cardiff $1.1M severance). Implications: Heightened bankruptcy risk in biotechs/SPACs, alpha in post-raise runways (e.g., OS Therapies to 2027), monitor Q2 catalysts like approvals/forbearance ends.

50 high priority 50 total filings
· daily

US Corporate Board Director Changes SEC Filings — April 02, 2026

Across 50 SEC 8-K filings on USA boardroom changes (42 new since last brief), C-suite turnover is elevated with 18 CFO/finance role shifts, 12 CEO/President changes, and 20 director/board adjustments, driven by retirements (10 cases), promotions (8), and experienced external hires (12). Sentiment skews positive/neutral (48/50), with 10 firms reaffirming 2026 guidance post-change (e.g., ESAB, Sally Beauty, Xerox), indicating continuity amid leadership refreshes; one negative (Regenerex CFO suspension) and one mixed (Kiora CDO departure). No broad revenue/margin declines; isolated YoY comp growth (Consumer Portfolio CEO +31%, Pres +44%) and bonus payouts (MAIA $362k total) signal strong FY2025 performance. Biotech (9 filings) and financials (8) lead activity, with net board size reductions in 5 cases. Implications: Positive for growth-oriented firms via M&A-savvy adds (Mama's Creations, Riverview); monitor interims (Oportun) for execution risk. Portfolio trend: Finance roles show +20% hire experience premium vs. average, no insider sales patterns.

50 high priority 50 total filings
· daily

US Merger & Acquisition SEC Filings — April 02, 2026

A surge in US M&A and takeover activity is evident across 20 filings on April 2, 2026, with 12 completions or announcements including strategic acquisitions in energy, pharma, retail, investment management, avionics, and buses, alongside 2 divestitures of non-core assets netting $24.8M and $70M cash respectively. SPACs dominate with 7 filings focused on unit separations, extensions, merger approvals, and amendments, signaling sustained deal hunting amid low redemptions (e.g., 1,153 shares in Tech & Tele). Positive sentiment prevails in 10/20 filings (50%), driven by accretive deals adding capacity (395MW Kodiak), AUM ($1.63B Bimini), revenue streams (Abundia Q2), and portfolio diversification, while mixed/neutral tones in divestitures and administrative updates. Period-over-period data limited but notable: Ashford pro forma revenue -1.6% YoY to $1.087B but net loss improved 16.5% to $157M excluding underperformer. No insider trading reported; forward-looking highlights include immediate accretion (Kodiak), Q2 revenue (Abundia), 2027 earnouts (Crown), and integration catalysts. Portfolio-level: M&A valuations range $200M-$1B EV, emphasizing bolt-ons for growth; implications point to sector consolidation in energy/industrials, SPAC revival.

20 high priority 20 total filings
· monthly

US Pre-Market SEC Filings Roundup — April 02, 2026

Overnight SEC filings reveal a heavy volume of proxy statements (20+ filings) signaling the ramp-up to May 2026 annual meetings, focusing on director elections, auditor ratifications, and equity plan approvals amid stable governance themes. Financial results are mixed: standout revenue growth in pharma (Pharming +26.6% YoY to $376M) and mining (Dynaresource +25.7% to $58M), contrasted by sharp declines in e-commerce (LightInTheBox -59.5% to $255M in 2024) and aesthetics (AirSculpt -15.8% FY25). M&A and restructuring activity is robust, including Kodiak's accretive $587M acquisition adding 395MW capacity and Suncrete's preferred stock exchange ahead of SPAC merger. Capital allocation leans shareholder-friendly with buybacks (FactSet $303M 6-mo, Lindsay $55M YTD, News Corp $1B program) and debt management (Transocean retiring $750M in 2026). Energy sector shines with Transocean's $1B backlog addition, while small-caps flag going concern risks (Mannatech, Algorhythm). Portfolio trend: 7/15 financial reporters show revenue growth averaging +15% YoY but mixed profitability; watch May catalysts for governance-driven volatility.

29 high priority 21 medium 50 total filings
· daily

Federal Construction & Infrastructure Contracts — April 01, 2026

Hensel Phelps Construction Co secured a $117M firm-fixed-price contract from USGS (DOI) for Hawaii facilities construction, with $84.3M (72%) already outlayed, providing strong revenue backlog through 2026. This sole award in the period highlights concentrated federal commitment to environmental infrastructure amid full-and-open competition. Execution risks from cost overruns and Hawaii logistics warrant monitoring, while $4.4M options offer upside.

1 total filings
· daily

DOD Defense Contracts Intelligence — April 01, 2026

Sevenson Environmental Services, Inc. secured a $180M (up to $199M with options) 8-year DoD contract for environmental remediation, signaling strong long-term revenue visibility for this small business. No funds outlaid yet delays near-term impact, but positions Sevenson for sustained growth in DoD cleanup efforts. Investors should monitor funding releases and options exercise amid execution risks over the 2024-2032 period.

1 total filings
· daily

Defense Manufacturing Contracts — April 01, 2026

Lockheed Martin benefits from a $301M NASA contract for MAVEN Mars project risk reduction, providing revenue visibility through Sep 2026 amid only 14% ($44M) outlayed to date. Remaining $257M obligation signals multi-year backlog in space manufacturing. Execution risks tied to performance-based award fees warrant monitoring, but long-term stability favors bullish positioning for institutional portfolios exposed to defense/space primes.

1 total filings
· daily

HHS & Healthcare Contracts Intelligence — April 01, 2026

Emergent BioSolutions secures $256M HHS contract for botulism antitoxin via Canadian subsidiary, providing multi-year revenue visibility to potential 2029 with $188M already outlayed. Bullish signal for steady biodefense revenue amid non-competed award, but firm-fixed-price structure and foreign ownership introduce execution and regulatory risks. Single large contract highlights HHS/ASPR focus on preparedness stockpiles, warranting monitoring for extensions.

1 total filings
· daily

New Federal Contractors — April 01, 2026

NASA commands 67% ($2.06B) of the $3.06B in new federal contract obligations, signaling sustained U.S. space investment through 2029+ with bullish awards to RTX/Raytheon ($1.22B), Lockheed ($301M), and others. Defense and environmental services see multi-year commitments to HII ($446M) and Sevenson ($180M), providing revenue backlogs amid 7/8 bullish signals. Long-duration cost-plus structures dominate, offering visibility but tying payouts to performance and appropriations.

8 total filings
· daily

Significant Contract Modifications ($10M+) — April 01, 2026

NASA dominates with $2.06B in long-term space contracts (67% of total value) to RTX/Raytheon, Lockheed Martin, TRAX, and Caltech/JPL, signaling sustained U.S. space investment through 2029 and bullish revenue visibility for aerospace primes. Additional $1B+ across DoD, HHS, GSA supports defense, health security, and environmental sectors via multi-year awards to HII, Emergent BioSolutions, and Sevenson. Overall bullish (7/8 signals) with $3.06B total obligations, but monitor funding outlays (avg. 40% disbursed) and appropriations risks amid extended timelines.

8 total filings
· daily

Contract Deobligations Alert — April 01, 2026

Eight contract deobligations alert $3.06B in total obligations, with 87% ($2.66B) tied to NASA and space-related work, signaling sustained U.S. government commitment to long-term aerospace projects through 2029 despite fiscal scrutiny. Bullish signals dominate (7/8) for primes like RTX, Lockheed Martin, and HII, driven by low-competition, cost-plus structures providing multi-year revenue visibility exceeding $900M in unobligated options. Risks center on execution over extended periods (avg. 10+ years) and funding dependencies, but opportunities in follow-ons favor sector leaders amid DoD/HHS diversification.

8 total filings
· daily

Contract Option Exercises — April 01, 2026

NASA dominates with $2.06B in long-term space contracts to RTX (Raytheon), Lockheed Martin, TRAX, and Caltech/JPL, signaling sustained U.S. space investment through 2029. Seven bullish signals across $3.06B total obligations highlight revenue visibility for defense primes and service providers via cost-plus structures. Key risks include execution over 5-18 year periods and funding dependencies on appropriations.

8 total filings
· daily

Federal Professional Services Contracts — April 01, 2026

HII Mission Technologies, subsidiary of Huntington Ingalls Industries, received a $446M obligated GSA engineering services award (potential $955M with options), underscoring robust federal demand in professional services. Unobligated options offer $509M near-term upside, but performance-tied fees and 2025 expiration introduce execution risks. This sole large contract highlights concentration risk in defense-adjacent engineering but signals potential for follow-ons.

1 total filings
· daily

NASA & Space Contracts Intelligence — April 01, 2026

NASA's two major ongoing contracts total $435M in obligations, with Lockheed Martin capturing a bullish $301M MAVEN Mars award (14% outlayed, $257M remaining through 2026) providing prime contractor revenue visibility. JPL's neutral $134M DSOC deep space comms project (73% outlayed, $36M remaining + $0.5M options to 2027) signals stable R&D funding. Cross-pattern: extended timelines highlight sustained deep space investment but expose execution and appropriation risks, favoring space primes with backlogs.

2 total filings